MIFH
ARCT icon

Migdal Insurance & Financial Holdings’s Arcturus Therapeutics ARCT Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-657
Closed -$5K – 461
2017
Q1 		$5K Buy
+657
New +$6.08K ﹤0.01% 452

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Migdal Insurance & Financial Holdings's ARCT Position: Q2 2017 in Review

Migdal Insurance & Financial Holdings sold out of Arcturus Therapeutics (ARCT) in Q2 2017, closing a stake of 657 shares — an estimated $5K sold.

Migdal Insurance & Financial Holdings first reported a position in ARCT in Q1 2017 and held it in 1 quarter. The position peaked at $5K in Q1 2017. 23 funds tracked by Wall St. Rank hold ARCT as of Q2 2017.

  • Migdal Insurance & Financial Holdings reported no remaining Arcturus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 657 Arcturus Therapeutics shares in Q2 2017, an estimated $5K.
  • Migdal Insurance & Financial Holdings first reported a position in Arcturus Therapeutics in Q1 2017 and held it in 1 quarter.
  • Migdal Insurance & Financial Holdings's Arcturus Therapeutics position peaked at $5K in Q1 2017.
  • 23 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2017.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2017, filed 15 Aug 2017.